Elizabeth A. Czerepak
Prior to Bear Stearns, Elizabeth Czerepak was Vice President for Business Development and a member of the Executive Board at BASF Pharma/Knoll Pharmaceutical Co., participating in the direction of all operational activities of the $890 million revenue U.S. company. She was also lead negotiator for several major global deals focused on strategic growth and product development.
Prior to BASF, Ms. Czerepak spent nine years at Hoffmann-La Roche in senior positions responsible for licensing, acquisitions, financial analysis and strategic planning. During that time she participated in over 25 transactions, including equity investments in biotechnology companies and the $5.4 billion acquisition of Syntex. She served as a liaison for Roche in managing strategic deal flow from its "window on technology" investments in the health care-focused venture capital funds of HealthCare Ventures, CW Group, Oxford Bioscience Partners, Advent, HealthCare Ventures, and others. At Roche, Ms. Czerepak established RIMB Ventures to facilitate spin-out companies which capitalized on innovation from the Roche Institute for Molecular Biology.
Ms. Czerepak began her pharmaceutical career at Merck & Co., where she was a key member of the team that developed the first comprehensive, simulation-based model for predicting R&D productivity. She received a B.A. magna cum laude from Marshall University and an MBA in Finance from Rutgers University.
BSHI portfolio: Ms. Czerepak currently serves on the board of directors of Agensys, Inc. and PharmAthene, Inc.
|
